(9ci)-1-甲基-1H-苯并咪唑-2-硫代甲酰胺 | 43102-10-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: (9ci)-1-甲基-1H-苯并咪唑-2-硫代甲酰胺
• 英文名称: 1-methyl-1H-benzoimidazole-2-carbothioic acid amide
• 英文别名: 1-methyl-1H-benzoimidazole-2-carbothioic acid amide；1-methyl-1H-benzimidazole-2-carbothioamide；1-Methyl-2-thiocarbamoylbenzimidazol；1H-Benzimidazole-2-carbothioamide, 1-methyl-；1-methylbenzimidazole-2-carbothioamide
• CAS: 43102-10-9
• 化学式: C₉H₉N₃S
• mdl: MFCD00196766
• 分子量: 191.257
• InChiKey: CKYJSBBYRYUROM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  75.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-氯乙酰乙酸乙酯 、 (9ci)-1-甲基-1H-苯并咪唑-2-硫代甲酰胺 以 乙醇 为溶剂， 反应 8.0h， 以57%的产率得到4-methyl-2-(1-methyl-1H-benzoimidazol-2-yl)-thiazole-5-carboxylic acid ethyl ester
  参考文献：
  名称：

  Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives

  摘要：

  A novel kind of thiazolylbenzimidazole derivatives were designed and synthesized and evaluated for their antitumor activity against SMMC-7721 and A549 cell lines. Most compounds showed good antitumor activities, and compound lib displayed remarkable in vitro anticancer activity comparable to taxol. The preliminary structure-activity relationship of these benzimidazole derivatives was discussed based on the experimental data obtained. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.11.014
• 作为产物：
  描述：

  (9ci)-1-甲基-1H-苯并咪唑-2-甲腈 在 ammonium sulfide 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以82%的产率得到(9ci)-1-甲基-1H-苯并咪唑-2-硫代甲酰胺
  参考文献：
  名称：

  Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives

  摘要：

  A novel kind of thiazolylbenzimidazole derivatives were designed and synthesized and evaluated for their antitumor activity against SMMC-7721 and A549 cell lines. Most compounds showed good antitumor activities, and compound lib displayed remarkable in vitro anticancer activity comparable to taxol. The preliminary structure-activity relationship of these benzimidazole derivatives was discussed based on the experimental data obtained. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.11.014

文献信息

• Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
  申请人：Sireen AG

  公开号：EP1555264A1

  公开（公告）日：2005-07-20

  The present invention refers to novel substituted aromatic heteroaryl derivatives of formula (I). with the definitions of A, L1, L2, G, J, X and Y according to claim 1. These novel compounds are useful for the inhibition of protein kinases, particularly of the inhibition of Src family protein kinases. Methods for inhibiting kinases by contacting kinases with these novel compounds are disclosed. In another embodiment the present invention refers to pharmaceutical compositions containing these novel compounds and their use for the preparation of medicaments for treating diseases or disorders associated with unphysiological activity of kinases in the body, particularly for the treatment of cancer, immunosuppression, and osteoporosis.

  本发明涉及公式（I）的新型取代芳香杂环衍生物，其中A、L1、L2、G、J、X和Y的定义如权利要求1所述。这些新型化合物对蛋白激酶的抑制具有用处，特别是对Src家族蛋白激酶的抑制。公开了通过将这些新型化合物与激酶接触来抑制激酶的方法。在另一实施方式中，本发明涉及含有这些新型化合物的药物组合物，以及它们用于制备用于治疗体内激酶非生理活性相关疾病或紊乱的药物，特别是用于癌症、免疫抑制和骨质疏松症的治疗。
• BUKOWSKI L., ACTA POL. PHARM. <APPH-AX>, 1975, 32, NO 6, 651-656
  作者：BUKOWSKI L.

  DOI：——

  日期：——
• FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SRC FAMILY PROTEIN KINASE
  申请人：Sirenade Pharmaceuticals AG

  公开号：EP1709040A2

  公开（公告）日：2006-10-11
• [EN] KINASE INHIBITOR COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE KINASES
  申请人：SIRENADE PHARMACEUTICALS AG

  公开号：WO2005068458A2

  公开（公告）日：2005-07-28

  The present invention refers to novel substituted aromatic heteroaryl derivatives of formula (I), with the definitions of a, L1, L2, G, J, X and Y according to claim 1. These novel compounds are useful for the inhibition of protein kinases, particularly of the inhibition of Src family protein kinases. Methods for inhibiting kinases by contacting kinases with these novel compounds are disclosed. In another embodiment the present invention refers to pharmaceutical compositions containing these novel compounds and their use of medicaments for treating diseases or disorders associated with unphysiological activity of kinases in the body, particularly for the treatment of cancer, immunosuppression, and osteoporosis.
• Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives
  作者：Yu Luo、Feng Xiao、Shijing Qian、Wei Lu、Bo Yang

  DOI：10.1016/j.ejmech.2010.11.014

  日期：2011.1

  A novel kind of thiazolylbenzimidazole derivatives were designed and synthesized and evaluated for their antitumor activity against SMMC-7721 and A549 cell lines. Most compounds showed good antitumor activities, and compound lib displayed remarkable in vitro anticancer activity comparable to taxol. The preliminary structure-activity relationship of these benzimidazole derivatives was discussed based on the experimental data obtained. (C) 2010 Elsevier Masson SAS. All rights reserved.